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Introduction
In the field of cancer gene therapy, most investigations have been related to the antitumor effect of cancer vaccines with transfected cytokine genes, 1-3 major histocompatibility antigen 4 and co-stimulatory molecule, 5 and most of these reports have been concerned with tumorigenicity and prophylactic vaccination effect. A certain efficacy of cancer vaccines with transduced genes of such cytokines as IL-2, 6 IL-4, 7 IL-6, 8 or granulocyte-macrophage colony-stimulating factor (GM-CSF) 9 has been shown, but only a few studies reported sufficient therapeutic effect of the vaccines in tumor-bearing mice. This could be because systemic antitumor immunity induced by cancer vaccines is insufficient to reject tumors. In particular, the effect of a cancer vaccine with a transfected cytokine gene would be insignificant in mice bearing low immunogenic tumors or large-sized tumors. Therefore, combination of vaccines with other modalities is thought to be necessary.
rIL-12 has attracted attention as a cytokine with potent antitumor effect, and its systemic administration has demonstrated remarkable therapeutic effects in several tumor cell lines. 10, 11 Biologically, IL-12 has been demonstrated directly to augment the cytotoxic activities of NK cells, LAK cells and CTL; to enhance the proliferation of activated NK cells and T cells; [12] [13] [14] and to induce the secretion of IFN-␥ from both NK cells and T cells. [15] [16] [17] Therefore, various trials have been conducted to apply
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Received 17 March 1998; accepted 15 July 1998 systemic administration of rIL-12 together with a vaccine therapy. Vaccination of B7-1 (a co-stimulatory molecule) gene 18 or IL-2 gene-transduced tumor cells, 19 of tumor peptide antigen, 20 or of dendritic cells pulsed with tumor antigen, 21 have exerted strong synergistic effects in combination with rIL-12.
In this study, we transfected the TNF gene into methylcholanthrene-induced fibrosarcoma (MCA-D), and investigated the therapeutic efficacy of a cancer vaccine in tumor-bearing mice. However, the result was unsatisfactory. Therefore, we used systemic administration of rIL-12 and investigated whether this combination therapy could enhance the insufficient systemic antitumor immunity induced by TNF gene-transduced cancer vaccines.
Results
TNF production in TNF gene-transduced tumor cells Twenty clones of TNF gene-transduced MCA-D cells were obtained by limiting dilution after G418 selection, and two of these clones (B10 and F10) were used in this study. B10 is a high-producer clone and produces TNF at a concentration of 2800 pg/ml per 10 6 cells in 48 h (measured by ELISA). F10 is a low-producer clone and produces TNF at a concentration of 110 pg/ml. Parental tumor cells do not produce TNF-␣ at a detectable level.
In vivo tumorigenicity of TNF gene-transduced tumor cells Tumor development following the TNF gene-transduced tumor cell implantation in syngeneic C3H/HeN mice is shown in Figure 1 . The vertical axis shows the average tumor diameter of each group of 10 mice. Growth of F10 cells was reduced in comparison with the parental cells (P Ͻ 0.05), but the reduction was significantly more apparent in B10 cells than in F10 cells (P Ͻ 0.01). Complete regression of tumor was observed in eight of the 10 mice which received B10, and in four of the 10 mice which received F10 (Figure 2 ). This effect was correlated pre-established parental tumors, but all mice could not reject pre-established parental tumors (Figure 4a ). Systemic rIL-12 alone also inhibited the growth of pre-established tumors in a dose-dependent manner up to 250 ng/mouse. However, no mice could reject pre-established parental tumors ( Figure 4b ) and 250 ng of rIL-12 was found to have lethal side-effects. In contrast, a combination of B10 tumor vaccine and systemic rIL-12 produced much more significant antitumor activity in comparison with either modality alone. When 125 or 62.5 ng of rIL-12 was co-administered with the vaccine, all mice rejected pre-established tumors (Figure 4c ). These tumors did not reappear until day 60. The mice which rejected the pre-established parental tumors were then rechallenged with 10 6 MCA-D cells or 10 6 MCA-F (a syngeneic fibrosarcoma cell line, which shows no cross-reactivity with MCA-D) on day 60. The mice which were rechallenged with MCA-D were able to reject the MCA-D, but the mice which received MCA-F developed progressive tumors and died. This showed that mice developed tumor-specific immunity against MCA-D cells.
IFN-␥ production by spleen cells
To investigate whether or not systemic antitumor immunity is augmented, we examined IFN-␥ production from spleen cells. Spleen cells of mice in each of the above-mentioned treatment groups were cultured for 48 h without exogenous tumor antigens. Figure 5 shows the result: IFN-␥ production was enhanced in the spleen cells of mice which were treated with either the TNF gene-transduced tumor vaccine (B10 cells) or rIL-12, in comparison with the control mice which received 10 5 parental tumor cells and no subsequent treatment. However, the increase in IFN-␥ production was more significant in the spleen cells of mice which were treated with a combination of the vaccine and rIL-12, than in the mice treated with either manipulation alone.
Cytotoxic activity
We then examined the cytotoxic activity of killer cells obtained from the spleen cells of mice by using the standard 51 Cr-release assay. Killer cells from the mice treated with both vaccine and rIL-12 showed enhanced cytotoxicity against parental tumor cells and YAC-1 cells in comparison with the mice which received either vaccine or rIL-12 ( Figure 6 ).
In vitro cell depletion of CD4
+ T cells, CD8 +
T cells and NK cells
To determine which population is responsible for the cytotoxicity of killer cells, cytotoxicity assays were perfor- 
Discussion
This study examined whether the therapeutic effect of TNF gene-transduced cancer vaccine is enhanced by systemic administration of rIL-12 in mice which bear a low immunogenic tumor, MCA-D. Neither the cancer vaccine nor systemic administration of rIL-12 alone achieved sufficient therapeutic effect. However, combination of these two manipulations enhanced the effect and the tumor completely regressed in all treated mice.
TNF is an antitumor cytokine, and possesses such biological activities as enhancement of monocyte, NK cells and neutrophil activities, [22] [23] [24] and augmentation of LAK and CTL development. In our study using a MCA-D cell line, we showed a decrease in tumorigenicity and prophylactic vaccination effect of TNF gene-transduced tumor cells, but sufficient therapeutic effect was not obtained. Therefore, we examined whether simultaneous systemic administration of rIL-12 enhances the therapeutic effect of TNF gene-transduced vaccine.
Vagliani et al 19 reported that systemic administration of rIL-12 potentiated the therapeutic effects of IL-2 gene- transduced tumor vaccine in the early stage of tumor growth. Coughlin et al 18 transduced B7-1 gene into poorly immunogenic SCK mammary carcinoma cells and examined the effect of B7-1 expression and systemic rIL-12 administration on tumorigenicity. They found that B7-1 alone modestly decreased tumorigenicity, and rIL-12 alone merely delayed it. However, when B7-1 and rIL-12 were applied together, SCK tumorigenicity was markedly inhibited. IL-12 is also demonstrated to induce Th1 cells and to enhance cellular (ie CD8 + CTL) immune responses against virus and bacterial infections, and IL-12 is reported to act as a tumor vaccine adjuvant. 31 Noguchi et al 20 investigated the effect of rIL-12 on p53 peptide vaccination against established Meth-A sarcoma. The antitumor effect of rIL-12 was dose dependent and regression of Meth-A tumor was seen in mice treated with a high dose of rIL-12. However, vaccines containing p53 peptide induced regression of the established Meth-A tumors in mice treated with low-dose rIL-12, but at that level rIL-12 itself did not show antitumor activity. Zitvogel et al 21 showed a potent effect of combination therapy using lowdose rIL-12 and dendritic cells which were pulsed with unfractionated tumor peptide extracted from autologous tumor. In this study, the combination of cancer vaccine and rIL-12 induced a synergistic therapeutic effect, and the efficacy was observed even when the dose of rIL-12 was reduced by half. Because IL-12 possesses toxic effects, as do the other cytokines, the decrease in dosage would also be important in reducing overall adverse reactions.
In order to clarify the mechanism of the synergistic effect induced by this combination therapy, we examined IFN-␥ production from spleen cells, cytotoxic activities of killer cells, and MHC class I antigen expression on genetransduced tumor cells.
rIL-12 strongly induces IFN-␥ production from T cells and NK cells, and this is quite important for its antitumor effects. Other studies have reported that IFN-␥ levels increased in culture supernatant of the spleen cells of mice which received systemic administration of rIL-12. 32 Gazzinelli et al 33 cultured spleen cells with IL-12 and TNF-␣, and found synergistic enhancement of IFN-␥ production. Based on these findings, we investigated IFN-␥ production levels in the culture supernatant of spleen cells obtained from the treated mice, and found that the levels increased in all the mice which received rIL-12 or vaccine alone, or the combination treatment, and the level in the mice which received both the vaccine and rIL-12 increased synergistically. This increase could be crucially related to systemic antitumor immunity, and act favorably to reject tumors.
The reasons for the escape of cancer cells from the host's immune system are not only the failure of antitumor immunity of the host, but also low immunogenicity of tumor cells, ie decreased recognition by T cells because of the decrease of MHC class I antigen expression on cancer cells, and induction of peripheral tolerance because of the absence of co-stimulatory molecule expression. Because tumor antigen is expressed on MHC class I, the increased expression of MHC class I antigen is important for TNF-or IL-12-activated CTL to recognize and attack cancer cells better. In fact, Fujii et al reported that TNF-␣ gene transduction into tumor cells enhances MHC class I antigen expression on the cellular surface, and this enhanced expression plays a role in the elevation of the host's systemic immunity. 29 We examined MHC class I antigen expression on TNF gene-transduced cancer cells using flow cytometry, and found that MHC class I antigen expression increased in clone B10 cells which produce TNF-␣ at a high level, in comparison with the parental cells. This could significantly influence the enhancement of the T cell-mediated immune response which is closely related to therapeutic efficacy. This is supported by the fact that in the cytotoxicity assay, killer cells showed enhanced cytotoxic activity against parental cells. Moreover, the killer cells showed cytotoxic activity against the non-specific target cells, YAC-1 cells. This suggests that not only tumor-specific CTL but also TNF-or IL-12-activated NK and/or LAK cells are important effector cells. To evaluate which population is responsible for the cytotoxic activity of killer cells, we examined the cytotoxic activity of killer cells using in vitro cell depletion. Treatment with either anti-CD8 mAb or anti-ASGM1 reduced cytotoxic activity. Anti-CD8 mAb in particular greatly reduced cytotoxicity. These results indicate that CD8 + T cells could be a main effector population in the rejection of pre-established tumor.
Dranoff et al 9 transduced genes of various cytokines into B16 melanoma cells, compared the efficacy of tumor vaccines, and reported that transduction of the GM-CSF gene induced the most potent therapeutic effect. However, it is still unclear whether a cytokine gene which is efficacious for one or a few tumor cell lines is also efficacious for other cell lines. Selection of efficacious cyto-kine genes is important for the clinical treatment of human cancers which are thought to be immunologically heterogeneous. On the other hand, as a means to augment the efficacy of cancer vaccine, several genes could be cotransfected to increase the immunogenicity of the cancer vaccine itself. However, cotransfection alone might still not be sufficient to induce the required systemic antitumor immunity. Thus, it is necessary to coadminister another treatment that can synergistically act with cytokine gene-transduced tumor vaccine and subsequently widen the spectrum of curable tumors. We demonstrated a favorable therapeutic effect of the vaccine, in combination with systemic rIL-12, against the tumor which did not regress sufficiently by TNF genetransduced cancer vaccine alone, and our findings indicate that systemic rIL-12 is able to serve as an adjuvant to cancer vaccine. The combination of cancer vaccine and low-dose rIL-12 will be a promising strategy in immunogene therapy for human cancer.
Materials and methods

Animals
Female C3H/HeN mice, 6 weeks of age, were purchased from Shimizu Experimental (Kyoto, Japan).
Tumor cells
Methylcholanthrene-induced fibrosarcoma (MCA-D) which is syngeneic to C3H/HeN mice was grown in complete medium which is made of RPMI 1640 (Nikken, Japan) supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/ml penicillin, 100 g/ml streptomycin, and 5 × 10 −5 m 2-mercaptoethanol; and the culture was maintained at 37°C in a humidified atmosphere containing 5% CO 2 .
Cytokine
Recombinant murine IL-12 (3 × 10 6 U/mg) was kindly provided by Genetic Institute (Cambridge, MA, USA).
Plasmid
We used pcDV-TNF, a simian virus 40-derived expression vector into which human TNF-␣ gene was inserted. It was kindly provided by Dr Yoshiro Niitsu, Sapporo Medical University, and was constructed by Asahi Chemical Industry (Tokyo, Japan).
Transfection of MCA-D with TNF gene
The lipofection method was used for the transfection. Briefly, 5 × 10 5 cells were plated on a 35-mm dish, washed twice with 3 ml of Opti-MEM I-reduced serum medium, and immersed in 0.8 ml of the same medium. The cells were cultured for 6 h at 37°C after the addition of 200 l of plasmid-lipofectin reagent mixture containing 2 g of pcDV-TNF, 0.2 g of pSV2neo and 20 l lipofectamine. Then, 1 ml of RPMI supplemented with 20% FCS was added. Neomycin-resistant cells were selected in 1000 g/ml G418 for 14 days starting from 3 days after the transfection. The selected transformants were cloned by the limiting dilution method. TNF production in each clone was determined by ELISA: each clone was cultured in a 10-cm dish at a concentration of 1 × 10 6 cells in 10 ml RPMI 1640 supplemented with 10% FCS. After incubation at 37°C in a humidified incubator (5% CO 2 ) for 48 h, supernatant was collected by filtration, and stored at −20°C until use. TNF-␣ content in the supernatant was assayed by enzyme-linked immunosorbent assay kit (TNF-␣ ELISA Kit; Genzyme, Cambridge, MA, USA). In vitro production of IFN-␥ and its assay Spleens of mice in each treatment group were resected aseptically, cut into small pieces, and passed gently through a stainless steel mesh. The cells were then centrifuged at 1600 g for 5 min and the pellet was resuspended in a lysing buffer to lyse red blood cells. The spleen cells were washed twice, resuspended in culture medium, and cultured in a 24-well plate at a concentration of 5 × 10 6 cells per one milliliter of culture medium. After incubation at 37°C in a humidified incubator (5% CO 2 ) for 48 h, supernatant was collected by filtration, and stored at −20°C until use. IFN-␥ content in the supernatant was determined by using ELISA kits (InterTest-␥, Mouse IFN-␥ ELISA Kit; Genzyme). All tests were performed in duplicate.
Implantation of tumor cells
Mixed lymphocyte-tumor cell culture (MLTC) Spleen cells were collected as described above, and 5 × 10 6 cells were cocultured with 2 × 10 5 irradiated (35 Gy) MCA-D cells in 2 ml of culture medium in a 24-well plate for 5 days at 37°C and 5% CO 2 . For the last 2 days, 80 IU/ml of IL-2 was added. Cr-labeled target cells in 96-well U-bottom microtiter plates (Costar, Cambridge, MA, USA). Maximum lysis was determined by adding 0.1 ml of TritonX 2%, and spontaneous release was determined by adding 0.1 ml culture medium to 1 × 10 4 target cells. After cell-cell contact was established by brief centrifugation, the cells were incubated for 4 h. The supernatants were collected and In vitro cell depletion These effector cells were depleted of specific cell populations using monoclonal antibody (mAb) and rabbit complement. Effector cells were induced by MLTC from spleen cells of mice treated with vaccines and rIL-12. Cells were incubated for 60 min at 4°C with respective mAb at optimal concentration, followed by incubation with rabbit complement (Low-Tox-M; Cedarlane, Ontario, Canada) for 60 min at 37°C. Anti-CD8 mAb (49-31.1) was obtained from Cedarlane. Anti-CD4 mAb (GK1.5) was obtained from Becton Dickinson. Anti-asialo GM1(anti-ASGM1) was obtained from Wako Pure chemical (Osaka, Japan).
Statistical analysis
Data were statistically analyzed using Student's t test.
